Hepatology

Papers
(The H4-Index of Hepatology is 73. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies2233
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction1923
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis1739
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury1191
Reply: Medications promoting abstinence in alcohol-associated cirrhosis464
Late-Breaking Abstracts325
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks277
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol252
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention241
Cover Image213
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!212
Letter to the editor: The precise relationship between MELD and survival without a liver transplant197
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency190
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet188
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8184
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST184
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis181
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation168
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals160
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study152
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution151
Access to technology to support telehealth in areas without specialty care for liver disease147
Reply145
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?133
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis126
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD124
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease124
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC122
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive122
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis119
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1116
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice116
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients113
Reply: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC111
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates108
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma106
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy105
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death104
Regulatory role and translational potential of CCL11 in liver fibrosis102
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH102
Plasma proteomic signature of fatty liver disease: The Rotterdam Study102
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor101
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis100
Efficacy and safety of infliximab in patients with autoimmune hepatitis98
96
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis96
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease96
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma95
Genes that fit just right: Unzipping the genome of fatty liver disease94
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?92
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm92
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?90
Reply90
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis89
Reply: The CRAPT-M score: Robust enough for clinical practice?89
89
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans88
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism88
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats87
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study87
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?85
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation85
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis82
Letter to the Editor: Overlooking the important factor: Hypoxia80
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known78
Letter to the editor76
Instructions to Authors75
The digital determinants of liver disease75
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis74
Healthy peribiliary glands are necessary for successful liver transplantation73
Reply: Diabetes and fibrosis—Parallel risks or overlap?73
Letter to the Editor: Insights into immune-mediated adverse events and survival outcomes—Lessons from HIMALAYA73
The international quest for the imaging diagnosis of liver cancer73
0.21720695495605